Mariam Simonyan

Human Resources Manager at IGM Biosciences, Inc. - Mountain View, California, US

Mariam Simonyan's Colleagues at IGM Biosciences, Inc.
Danielle Galindo

Quality Assurance Specialist

Contact Danielle Galindo

Rachel Mejia

Clinical Program Manager

Contact Rachel Mejia

Sijia He

Scientist II, Infectious Diseases

Contact Sijia He

Jessica Schroder

Talent Acquisition Coordinator

Contact Jessica Schroder

Keyu Li

Senior Scientist

Contact Keyu Li

View All Mariam Simonyan's Colleagues
Mariam Simonyan's Contact Details
HQ
(650) 965-7873
Location
Company
IGM Biosciences, Inc.
Mariam Simonyan's Company Details
IGM Biosciences, Inc. logo, IGM Biosciences, Inc. contact details

IGM Biosciences, Inc.

Mountain View, California, US • 258 Employees
BioTech/Drugs

About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).

Lymphoma Treatment Hematologic Malignancies Autoimmune Disease
Details about IGM Biosciences, Inc.
Frequently Asked Questions about Mariam Simonyan
Mariam Simonyan currently works for IGM Biosciences, Inc..
Mariam Simonyan's role at IGM Biosciences, Inc. is Human Resources Manager.
Mariam Simonyan's email address is ***@igmbio.com. To view Mariam Simonyan's full email address, please signup to ConnectPlex.
Mariam Simonyan works in the BioTech/Drugs industry.
Mariam Simonyan's colleagues at IGM Biosciences, Inc. are Danielle Galindo, Dominique Durant, Rachel Mejia, Sijia He, Jessica Schroder, Todd Metzger, Keyu Li and others.
Mariam Simonyan's phone number is (650) 965-7873
See more information about Mariam Simonyan